In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) closed at $74.95 up 7.33% from its previous closing price of $69.83. In other words, the price has increased by $7.33 from its previous closing price. On the day, 0.72 million shares were traded. TARS stock price reached its highest trading level at $75.01 during the session, while it also had its lowest trading level at $68.8001.
Ratios:
For a deeper understanding of Tarsus Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.21 and its Current Ratio is at 5.26. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
On November 20, 2023, Goldman started tracking the stock assigning a Neutral rating and target price of $19.Goldman initiated its Neutral rating on November 20, 2023, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 24 ’25 when Azamian Bobak R. sold 6,000 shares for $55.37 per share. The transaction valued at 332,220 led to the insider holds 812,106 shares of the business.
Bobak Azamian Living Trust bought 6,000 shares of TARS for $332,208 on Sep 24 ’25. On Sep 08 ’25, another insider, LINK WILLIAM J PHD, who serves as the Director of the company, sold 27,116 shares for $57.00 each. As a result, the insider received 1,545,612 and left with 143,332 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 3163947008 and an Enterprise Value of 2855250176. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.71 while its Price-to-Book (P/B) ratio in mrq is 9.51. Its current Enterprise Value per Revenue stands at 9.662 whereas that against EBITDA is -29.613.
Stock Price History:
The Beta on a monthly basis for TARS is 0.79, which has changed by 0.8837335 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $71.15, while it has fallen to a 52-week low of $35.84. The 50-Day Moving Average of the stock is 30.70%, while the 200-Day Moving Average is calculated to be 52.73%.
Shares Statistics:
For the past three months, TARS has traded an average of 680.13K shares per day and 698760 over the past ten days. A total of 42.21M shares are outstanding, with a floating share count of 38.61M. Insiders hold about 8.53% of the company’s shares, while institutions hold 108.18% stake in the company. Shares short for TARS as of 1759190400 were 7243632 with a Short Ratio of 10.65, compared to 1756425600 on 6925599. Therefore, it implies a Short% of Shares Outstanding of 7243632 and a Short% of Float of 17.740000000000002.
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of Tarsus Pharmaceuticals Inc (TARS) in the stock market.The consensus estimate for the next quarter is -$0.05, with high estimates of $0.0 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$1.44 and -$1.56 for the fiscal current year, implying an average EPS of -$1.5. EPS for the following year is -$0.23, with 3.0 analysts recommending between $0.86 and -$2.15.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $114.22M this quarter.It ranges from a high estimate of $118.92M to a low estimate of $109.93M. As of. The current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $48.12MFor the next quarter, 6 analysts are estimating revenue of $130.74M. There is a high estimate of $137.26M for the next quarter, whereas the lowest estimate is $124.24M.
A total of 7 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $439.98M, while the lowest revenue estimate was $415.16M, resulting in an average revenue estimate of $427.17M. In the same quarter a year ago, actual revenue was $182.95MBased on 6 analysts’ estimates, the company’s revenue will be $612.85M in the next fiscal year. The high estimate is $715.08M and the low estimate is $464.91M.
